吉非替尼联合白蛋白结合型紫杉醇对NSCLC患者生活质量和生存期的影响

doi:10.19803/j.1672-8629.2021.06.14

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (6): 562-565.
DOI: 10.19803/j.1672-8629.2021.06.14

吉非替尼联合白蛋白结合型紫杉醇对NSCLC患者生活质量和生存期的影响

曹洪丽¹, 于盼盼², 杨静³, 席家宁^1,*

¹首都医科大学附属北京康复医院,北京 100144;
²河北科技学院护理与健康学院基础医学教研室,河北保定 071000;
³山东省立第三医院,山东济南 250000

收稿日期:2021-03-05 出版日期:2021-06-15 发布日期:2021-07-02
通讯作者: ^*席家宁,男,主任医师,呼吸内科学。E-mail: baobao914@126.com
作者简介:曹洪丽,女,副主任医师,呼吸内科学。
基金资助:
山东省自然科学基金资助项目（ZR2019PH107）; 2020年山东省医学会治疗药物监测科研基金（YXH2020ZX047）; 首都医科大学附属北京康复医院科技发展专项立项（2019-002）

Effect of Gefitinib Combined with Paclitaxel on Quality of Life and Survival in Patients with NSCLC

CAO Hongli¹, YU Panpan², YANG Jing³, XI Jianing^1,*

¹Beijing Rehabilitation Hospital Affiliated to Capital Medical University, Beijing 100144, China;
²Department of Basic Medicine, College of Nursing and Health, Hebei University of Science and Technology,Baoding Hebei 071000, China;
³Shandong Provincial Third Hospital, Jinan Shandong 250000, China

Received:2021-03-05 Online:2021-06-15 Published:2021-07-02

摘要/Abstract

摘要： 目的探究吉非替尼联合白蛋白结合型紫杉醇化疗方案对晚期非小细胞肺癌（non small cell lung cancer, NSCLC）患者生活质量、生存期的影响,分析其临床价值。方法选取90例晚期NSCLC患者,随机分为观察组、对照组,对照组予白蛋白结合型紫杉醇、顺铂治疗,观察组加用吉非替尼。比较2组患者临床疗效、不良反应、生活质量及癌症标志物变化,并对比2组生存期。结果治疗3个月后,观察组有效率、疾病控制率分别为55.56%、84.44%,均高于对照组的22.22%、60.00%（P<0.05）。2组治疗期间不良反应发生率比较,差异无统计学意义（P>0.05）。治疗6个月后,2组生活质量均较治疗前改善,观察组治疗6个月后简明生活质量调查量表（SF-36）各领域得分均高于对照组同时期水平（P<0.05）。治疗3个月后,2组癌胚抗原（CEA）、糖类抗原50（CA50）、糖类抗原125（CA125）均较治疗前下降,观察组治疗6个月后上述指标均低于对照组同时期水平（P<0.05）。观察组无进展生存期为（5.97±0.88）个月,3年生存率为42.22%,均高于对照组的（3.62±0.74）个月、24.44%（P<0.05）。结论在白蛋白结合型紫杉醇、顺铂化疗方案的基础上,加用吉非替尼能够明显提高晚期NSCLC患者生活质量,延长生存期,在保证治疗安全性的前提下取得更为理想的临床疗效。

关键词: 吉非替尼, 白蛋白结合型紫杉醇, 非小细胞肺癌, 生活质量

Abstract: Objective To investigate the effect of gefitinib combined with paclitaxel on the quality of life and survival of patients with advanced non-small cell lung cancer (NSCLC), and analyze its clinical value. Methods Ninety patients with advanced NSCLC admitted to our hospital were randomly divided into the observation group and control group. The control group was treated with albumin binding paclitaxel and cisplatin, while the observation group was additionally given gefitinib. The clinical efficacy, adverse reactions, quality of life and changes of cancer markers were compared between the two groups. Results After 3 months of treatment, the effective rate and disease control rate of the observation group were 55.56% and 84.44% respectively, which were higher than 22.22% and 60.00% of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P<0.05). After 6 months of treatment, the quality of life in the two groups was improved, and the scores of SF-36 in each field in the observation group were higher than those of the control group (P<0.05) in the same period. After 3 months of treatment, levels of CEA, CA50 and CA125 in the two groups decreased. After 6 months of treatment, the above indexes in the observation group were lower than those of the control group (P<0.05). The progression free survival time and 3-year survival rate of the observation group were (5.97±0.88) months and 42.22% respectively, which were higher than (3.62±0.74) months and 24.44% in the control group (P<0.05). Conclusion Combined with albumin binding paclitaxel and cisplatin chemotherapy, gefitinib can significantly improve the quality of life, prolong the survival of patients with advanced NSCLC, and achieve a better clinical effect while ensuring the safety of treatment.

Key words: gefitinib, albumin binding paclitaxel, non-small cell lung cancer, quality of life

中图分类号:

R979.1

曹洪丽, 于盼盼, 杨静, 席家宁. 吉非替尼联合白蛋白结合型紫杉醇对NSCLC患者生活质量和生存期的影响[J]. 中国药物警戒, 2021, 18(6): 562-565.

CAO Hongli, YU Panpan, YANG Jing, XI Jianing. Effect of Gefitinib Combined with Paclitaxel on Quality of Life and Survival in Patients with NSCLC[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 562-565.

参考文献

[1] Zhong WZ, Wang Q, Mao WM, et al.Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. The Lancet Oncology, 2018, 19(1): 139-148.
[2] Yue J, Lgu D, Wang C, et al.Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3[J]. Oncogene, 2018, 37(31): 4300-4312.
[3] Hosomi Y, Morita S, Sugawara S, et al.Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study[J]. Journal of Clinical Oncology, 2020, 38(2): 115-123.
[4] Sutiman N, Tan SW, Tan EH, et al.EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced Asian NSCLC patients[J]. Journal of Thoracic Oncology, 2017, 12(3): 529-538.
[5] Sun YP, Niu RG, Liu XX, et al.Effect of gefitinib on advanced non-small cell lung cancer with different EGFR site mutations[J]. Cancer Research and Clinical(肿瘤研究与临床), 2019, 31(5): 315-319.
[6] Xue YH, Wang LC, Hu LL, et al.Clinical efficacy and safety evaluation of nedaplatin or cisplatin combined with gemcitabine in the treatment of advanced NSCLC[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 12-15.
[7] Li X, Zhang X, Yang C, et al.The lncRNA RHPN1-AS1 downre-gulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC[J]. Cell Cycle, 2018, 17(14): 1772-1783.
[8] Li Q, Zhang JK, Liu ZH, et al.Clinical observation of gefitinib and chemotherapy in maintenance treatment of advanced non-small cell lung cancer[J]. International Medical and Health Guide(国际医药卫生导报), 2017, 23(16): 2568-2573.
[9] Kani K, Garri C, Tiemann K, et al.JUN-mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines[J]. Molecular Cancer Therapeutics, 2017, 16(8): 1645-1657.
[10] Yang JCH, Gadgeel SM, Sequist LVD, et al.Pembrolizumab in combination with Erlotinib or Gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation[J]. Journal of Thoracic Oncology, 2019, 14(3): 553-559.
[11] Zhao L, Lin T.The relationship between K-ras gene mutation and the effect of gifetinib in the treatment of advanced non-small cell lung cancer[J]. Chinese Journal of Experimental Surgery(中华实验外科杂志), 2019, 36(3): 445-445.
[12] Tan EH, Lim WT, Ahn MJ, et al.Phase 1b trial of ficlatuzumab, a humanized hepatocyte growth factor inhibitory monoclonal antibody, in combination with gefitinib in Asian patients with NSCLC[J]. Clinical Pharmacology in Drug Development, 2018, 7(5): 532-542.
[13] Zhang JB, Gao YF.Effect observation of hydroxycamptothecin pericardial perfusion combined with gefitinib in the treatment of advanced non-small cell lung cancer with pericardial effusion[J]. Chinese Basic Medicine(中国基层医药), 2019, 26(8): 968-971.
[14] Ma Y, Xin S, Huang M, et al.Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmaco-genomic study of metabolic enzymes and transporters[J]. The Pharmacogenomics Journal, 2017, 17(4): 325-330.
[15] Zhu C, Cai ZA, Li XY, et al.Clinical study of gefitinib combined with concurrent thoracic radiotherapy in the treatment of locally advanced non-small cell lung cancer with sensitive gene mutation[J]. China Basic Medicine(中国基层医药), 2019, 26(8): 943-948.
[16] Cho JH, You YM, Yeom YI, et al.RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation[J]. Cell Death & Disease, 2018, 9(6): 1-13.
[17] Tan J, Li M, Zhong W, et al.Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model[J]. Oncotarget, 2017, 8(58): 98771.
[18] Zheng Y.Effect of gefitinib combined with DP chemotherapy regimen combined with 3D-CRT on serum SCCAg, bFGF levels and survival cycle of patients with locally advanced non-small cell lung cancer[J]. International Journal of Medicine and Health(国际医药卫生导报), 2018, 24(13): 1974-1978.

吉非替尼联合白蛋白结合型紫杉醇对NSCLC患者生活质量和生存期的影响

Effect of Gefitinib Combined with Paclitaxel on Quality of Life and Survival in Patients with NSCLC

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

[1]	梁艳, 闫加庆, 杨珺. 注射用培美曲塞二钠致双侧小腿罕见硬皮样皮肤1例分析[J]. 中国药物警戒, 2023, 20(11): 1293-1295.
[2]	林琦琪, 李馨阳, 孟繁浩. 非小细胞肺癌培美曲塞的耐药机制研究[J]. 中国药物警戒, 2023, 20(11): 1201-1208.
[3]	吴颖其, 朱婷, 童彤, 李民, 沈爱宗. 白蛋白结合型紫杉醇不良反应/事件相关因素分析[J]. 中国药物警戒, 2022, 19(10): 1123-1127.
[4]	徐宝余, 沈华, 李歆, 韩峰. 化疗联合安罗替尼在晚期胰腺癌中的观察分析[J]. 中国药物警戒, 2022, 19(1): 72-73.
[5]	廖玉芳, 岳建农, 司可. 吉非替尼片致严重血清转氨酶升高伴急性胆囊炎1例分析[J]. 中国药物警戒, 2021, 18(6): 584-587.
[6]	张丛惠, 崔小康, 彭婷婷, 鹿岩, 郭琳琳, 刘健. 奥希替尼治疗EGFR突变的晚期非小细胞肺癌疗效与安全性的Meta分析[J]. 中国药物警戒, 2021, 18(2): 178-183.
[7]	樊鹏利, 鲁乐乐, 王漪檬, 刘银萍. 吉非替尼片致暴发性紫癜药品不良反应1例分析[J]. 中国药物警戒, 2020, 17(7): 441-443.
[8]	薛雁鸿, 王来成, 胡丽丽，*, 杨波. 奈达铂或顺铂联合吉西他滨治疗中晚期NSCLC的临床效果及其安全性评价[J]. 中国药物警戒, 2018, 15(3): 136-139.
[9]	张敬伟, 段冬梅, 袁小笋, 孙君重, 任中海* . 沙利度胺联合化疗治疗老年晚期非小细胞肺癌的临床观察[J]. 中国药物警戒, 2017, 14(8): 460-463.
[10]	别志欣, 丁丽. 吉非替尼与厄洛替尼致间质性肺病的临床特点分析[J]. 中国药物警戒, 2017, 14(5): 309-312.
[11]	夏惠红. 82例吉非替尼不良反应的文献分析[J]. 中国药物警戒, 2016, 13(2): 98-102.
[12]	陈澈, 院立新, 李净娅, 张根明. 活血化瘀方案对脑出血患者生活质量改善的影响[J]. 中国药物警戒, 2014, 11(8): 462-464.
[13]	张友文, 魏怀玲, 鲍秀琦, 张丹, 孙华. 双环醇对顺铂联合吉西他滨致荷瘤小鼠肝肾损伤的保护作用[J]. 中国药物警戒, 2014, 11(5): 257-260.
[14]	赵燕, 张茹. 厄洛替尼治疗非小细胞肺癌的机制、现状与展望[J]. 中国药物警戒, 2010, 7(10): 617-619.